Wall Street brokerages predict that Gemphire Therapeutics Inc (NASDAQ:GEMP) will report earnings per share (EPS) of ($0.45) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Gemphire Therapeutics’ earnings, with estimates ranging from ($0.48) to ($0.41). Gemphire Therapeutics posted earnings per share of ($0.82) during the same quarter last year, which would suggest a positive year-over-year growth rate of 45.1%. The company is scheduled to issue its next earnings results on Monday, November 12th.
According to Zacks, analysts expect that Gemphire Therapeutics will report full year earnings of ($1.88) per share for the current year, with EPS estimates ranging from ($1.89) to ($1.86). For the next year, analysts expect that the company will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.50) to ($1.59). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Gemphire Therapeutics.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its earnings results on Monday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.05.
GEMP traded down $0.01 during midday trading on Friday, reaching $1.77. 101,753 shares of the company were exchanged, compared to its average volume of 480,611. The company has a current ratio of 4.64, a quick ratio of 4.64 and a debt-to-equity ratio of 0.50. Gemphire Therapeutics has a one year low of $0.83 and a one year high of $11.43. The stock has a market cap of $29.39 million, a P/E ratio of -0.55 and a beta of 0.90.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC raised its position in shares of Gemphire Therapeutics by 100.0% during the first quarter. Segall Bryant & Hamill LLC now owns 30,000 shares of the company’s stock worth $195,000 after purchasing an additional 15,000 shares during the period. Northern Trust Corp raised its position in shares of Gemphire Therapeutics by 63.7% during the first quarter. Northern Trust Corp now owns 30,080 shares of the company’s stock worth $196,000 after purchasing an additional 11,708 shares during the period. JBF Capital Inc. acquired a new stake in shares of Gemphire Therapeutics during the second quarter worth about $204,000. Acadian Asset Management LLC acquired a new stake in shares of Gemphire Therapeutics during the second quarter worth about $286,000. Finally, Nomura Holdings Inc. acquired a new stake in shares of Gemphire Therapeutics during the second quarter worth about $556,000. 32.60% of the stock is currently owned by institutional investors.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.
Featured Article: Does the discount rate affect the economy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.